Peer-reviewed veterinary case report
Maropitant and loperamide help reduce chemo side effects in dogs
By Cartagena-Albertus, Juan C et al.·Published in American journal of veterinary research·2019·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Assessment of the administration of maropitant and loperamide to dogs with cancer for the prevention and reduction of adverse effects associated with the administration of paclitaxel.
- Species:
- dog
Plain-English summary
A group of 168 dogs with cancer were treated with a combination of maropitant and loperamide to help prevent or reduce stomach issues caused by the chemotherapy drug paclitaxel. The dogs that received both medications experienced fewer side effects, such as lack of appetite and lethargy, and these symptoms lasted for a shorter time compared to those who only received paclitaxel. In a follow-up phase, dogs that had previously experienced side effects showed significant improvement after being given maropitant and loperamide. Overall, this combination treatment was found to be safe and effective for managing gastrointestinal problems in dogs undergoing chemotherapy.
People also search for: dog cancer treatment side effects · maropitant for dogs nausea · loperamide for dog diarrhea
Abstract
OBJECTIVE: To evaluate the efficacy of maropitant and loperamide for the prevention and reduction of adverse gastrointestinal effects associated with administration of paclitaxel to dogs with cancer. ANIMALS: 168 dogs with cancer. PROCEDURES: The study comprised 2 phases. For phase 1, dogs in the intervention group were administered maropitant and loperamide followed by paclitaxel. Outcomes were compared with those for a control group that received only maropitant and paclitaxel. For phase 2, all dogs of phase 1 that did not receive maropitant and loperamide and that had adverse gastrointestinal effects were enrolled; they received maropitant and loperamide and another dose of paclitaxel. RESULTS: In phase 1, significantly fewer dogs in the intervention group had adverse effects. For dogs that had adverse effects, the intervention group had a lower severity of lack of appetite and lethargy. Also, adverse effects for dogs in the intervention group were of significantly shorter duration than for the control group. In phase 2, significant reductions in adverse effects were observed after administration of maropitant and loperamide. In those dogs that still had adverse effects after administration of maropitant and loperamide, there was a significant reduction in severity of signs of nausea and lethargy. CONCLUSIONS AND CLINICAL RELEVANCE: A combination of maropitant and loperamide was found to be safe for use and effective for reducing or preventing signs of paclitaxel-induced gastrointestinal effects in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31140850/